Characteristics of hepatitis C virus infection in HIV-infected people

Canadian Journal of Infectious Diseases

Volumn 12, Issue 3, 2001, Pages 157-163

  Cooper, C L ^a   Badley, A D ^a   Angel, J B ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antiretrovirals; HCV; Hepatitis; Hepatitis C virus; HIV; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; LIVER TOXICITY; LYMPHOCYTE COUNT; REVIEW; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION;

EID: 0034961645     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/542056     Document Type: Review

References (84)

1. The epidemiology of hepatitis C in the West
2. Antibody to hepatitis C virus in selected groups of a Canadian urban population
3. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
4. Clinical and epidemiologic characteristics of hepatitis C in a gastroenterology/hepatology practice in Ottawa
5. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study
6. Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients: Prevalence and prognostic value
7. Correlates of hepatitis C virus infections among drug users
8. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals
9. Interferon and ribavirin therapy for hepatitis C in HIV-coinfected patients
10. Antibody response to core, envelope, and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients
11. Immunological and virological characteristics of HCV co-infection in a cohort of HIV-infected individuals
12. Full or partial seroreversion in patients infected by hepatitis C virus
13. Interferon α-2b or in combination with ribavirin as initial treatment for chronic hepatitis C
14. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
15. HIV increases hepatitis C viraemia irrespective of hepatitis C viral genotype
16. Increasing hepatitis C virus RNA levels in haemophiliacs: Relationship to human immunodeficiency virus infection and liver disease
17. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia
18. HIV-HCV RNA levels and liver failure in coinfected patients with coagulopathy
19. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters
20. Predictors of detectable hepatitis C virus RNA (HCV-RNA) levels in HIV+/HCV+patients
21. The effect of CCR5Δ32 heterozygosity on hepatitis C viral load in HIV-1 infected individuals
22. Association between CCR5 genotype and the clinical course of HIV-1 infection
23. Hepatitis C virus type Ib (II) infection in France and Italy
24. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA
25. Impact of human immunodeficiency virus infection virus infection on the histological features of chronic hepatitis C: A case-control study
26. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients
27. The progression of HCV-associated liver disease in a cohort of haemophilic patients
28. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effects of coinfection with human immunodeficiency virus
29. HIV infection modifies the nature history of chronic parenterally aquired hepatitis C with an unusually rapid progression to cirrhosis. A multicenter study on 547 patients
30. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C
31. Liver histology in patients with concurrent chronic hepatitis C and HIV infection
32. Human immunodeficiency virus infection and hepatitis C pathology
33. An algorithm for the grading of activity in chronic hepatitis C
34. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
35. Hepatitis C virus (HCV) genotype does not appear to be a significant prognostic factor in HIV-HCV-coinfected patients
36. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype
37. The relationship of histology to genotype in chronic HCV infection
38. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C
39. Hepatitis C virus infection in the development of hepatocellular carinoma in cirrhosis
40. Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels
41. Natural history of liver fibrosis progression in patients with chronic hepatitis C
42. Clinical histological, and virological features of hepatitis C virus carriers with persistently normal and abnormal transaminase levels
43. Treatment with recombinant a-interferon of chronic hepatitis C in anti-HIV-positive patients
44. Efficiency of interferon for chronic hepatitis C in HIV+ patients
45. + cell count
46. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
47. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
48. Interferon plus-ribavirin for chronic hepatitis C in HIV-infected patients
49. Efficacy of combination therapy with interferon alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients
50. Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV-coinfected patients. 12-Month follow-up
51. Interferon + ribavirin in HIV + patients with chronic hepatitis C
52. Combination therapy with didanosine and interferon-α in human immunodeficiency virus-infected patients: Results of a phase I/II trial
53. + cell counts > 150 × 10E6/L: Results of the Zidon trial
54. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
55. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients
56. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
57. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type I infection and prior antiretroviral therapy
58. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection tn adults. Study 006 team
59. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy
60. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral therapy
61. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
62. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 20 per cubic millimeter or less
63. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir and saquinavir
64. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trial Group Protocol 315
65. Alterations in the response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
66. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
67. Hepatic steatosis and lactic acidosis associated with stavudine treatment in a HIV patient: A case report
68. Severe anoxic hepatic necrosis in a HIV-1-hepatitis C virus co-infected patient starting antiretroviral triple combination therapy
69. Hepatotoxicity after introduction of highly active antiretroviral therapy
70. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
71. Severe hepatitis in three AIDS patients treated with indinavir
72. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
73. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy
74. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient
75. Ribavirin antagonizes the effect of azidothymidine on HIV replication
76. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances the inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro
77. + lymphocytes in HIV-infected patients receiving interferon therapy for chronic hepatitis C
78. Rapid decline of CD4+ cells after IFNα treatment in HIV-1 infection
79. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type I disease: Evidence for drug safety, tolerance, and antiviral activity
80. High dose interferon-α2a exerts potent activity against human immunodeficiency virus type I not associated with antitumor activity in subjects with Kaposi's sarcoma
81. Biochemistry and clinical applications of ribavirin
82. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 postive patients under antiretroviral treatment
83. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
84. Management guidelines for the HIV and HIV co-infected adult: Recommendations of a nultidisciplinary expert panel